期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 109, 期 51, 页码 21134-21139出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1202906109
关键词
allosteric modulation; psychopharmacology; GPCR; inflammation; neuroprotection
资金
- German research foundation Deutsche Forschungsgemeinschaft [FOR926]
- Institut National de la Sante et de la Recherche Medicale
- Aquitaine Region
- European Research Council [ERC-2010-StG-260515]
- Fondation pour la Recherche Medicale
- Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)
- PRONEX
- Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico-CNPq
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Allosteric modulation of G-protein-coupled receptors represents a key goal of current pharmacology. In particular, endogenous allosteric modulators might represent important targets of interventions aimed at maximizing therapeutic efficacy and reducing side effects of drugs. Here we show that the anti-inflammatory lipid lipoxin A(4) is an endogenous allosteric enhancer of the CB1 cannabinoid receptor. Lipoxin A(4) was detected in brain tissues, did not compete for the orthosteric binding site of the CB1 receptor (vs. H-3-SR141716A), and did not alter endocannabinoid metabolism (as opposed to URB597 and MAFP), but it enhanced affinity of anandamide at the CB1 receptor, thereby potentiating the effects of this endocannabinoid both in vitro and in vivo. In addition, lipoxin A(4) displayed a CB1 receptor-dependent protective effect against beta-amyloid (1-40)-induced spatial memory impairment in mice. The discovery of lipoxins as a class of endogenous allosteric modulators of CB1 receptors may foster the therapeutic exploitation of the endocannabinoid system, in particular for the treatment of neurodegenerative disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据